Recommendation of the President – Libtayo (cemiplimab)
On 26 November 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 135/2024 on the appraisal Libtayo (cemiplimab) in the drug program B.6. “Treatment of patients with lung cancer (ICD-10: C34) and pleural mesothelioma (ICD-10: C45)”